Cargando…
Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report
BACKGROUND: Pembrolizumab has significantly improved outcomes in patients with advanced non-small cell lung cancer. Combining programmed death-1 inhibitor with stereotactic body radiotherapy showed a slight toxicity and good benefits in recent clinical trials. However, patients infected with human i...
Autores principales: | Li, Dongqi, He, Chuanchun, Xia, Yaoxiong, Du, Yaxi, Zhang, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911965/ https://www.ncbi.nlm.nih.gov/pubmed/29681240 http://dx.doi.org/10.1186/s13256-018-1667-2 |
Ejemplares similares
-
Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer
por: Woodford, Katrina, et al.
Publicado: (2017) -
Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer
por: Liu, Xiaoli, et al.
Publicado: (2023) -
Stereotactic Body Radiotherapy for Small Lung Tumors in the University of Tokyo Hospital
por: Yamashita, Hideomi, et al.
Publicado: (2014) -
Stereotactic body radiotherapy in lung cancer: an update
por: Abreu, Carlos Eduardo Cintra Vita, et al.
Publicado: (2015) -
Editorial: Stereotactic body radiotherapy for lung cancer
por: Liu, An, et al.
Publicado: (2023)